
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
This trial compared lenalidomide with a dummy drug (placebo) to see if it stopped chronic lymphocytic leukaemia coming back after second line chemotherapy. It was for people with B cell chronic lymphocytic leukaemia that had responded to 2nd line treatment.
This trial started in 2009 and the results were published in 2017.
Treatment for chronic lymphocytic leukaemia (CLL) is usually chemotherapy. When the first treatment stops working, your doctor may suggest you have another type. This is called second line treatment.
Lenalidomide is a type of targeted cancer drug. It works mainly by helping the body’s target cancer cells.
The aim of this trial was to find out if lenalidomide stopped B cell CLL coming back after responding to second line chemotherapy.
The trial team concluded that lenalidomide can help stop B cell CLL coming back after 2nd line treatment. And that lenalidomide wouldn’t affect how well any future treatment would work.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Andrew Pettitt
Celgene Corporation
ICON Clinical Research (UK) Limited
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.